Intracervical Vasopressin

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-51
SponsorPrisma Health-Upstate

About this trial

This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus.

The main goal of the study is :

• To add to the existing research through this study to see if the injection of intracervical vasopressin leads to improved completion rates of hysteroscopic management of RPOC.

Participants will:

• would be randomized to receive either vasopressin intracervical injection or a placebo injection (non-active saline) during your procedure. Information from the procedure will be collected from the participant's medical record.

Eligibility criteria

Qualifiers

Women

Aged 18-51

Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion

Disqualifiers

Hemodynamic instability

Active hemorrhage- soaking pad/hour

Allergy to vasopressin

Concern for intrauterine arteriovenous malformation

Trial design

Treatments tested in this trial

  • Intracervical injection of Vasopressin
  • Intracervical Injection of saline

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators